Cover Image
市場調查報告書

思覺失調症伴隨的認知障礙 (CIAS):開發中產品分析 (2015年下半年)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255980
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
思覺失調症伴隨的認知障礙 (CIAS):開發中產品分析 (2015年下半年) Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 104 Pages
簡介

思覺失調症的患者會出現輕∼重度的認知機能障礙。主要症狀有執行機能低落、難以維持集中力、工作記憶相關的問題等。致病因素有家族病史及年齡、自體免疫疾病等。主要治療法有給予抗精神病藥等。

本報告提供全球各國治療思覺失調症伴隨的認識功能障礙 (以下簡稱CIAS) 所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

CIAS (思覺失調症伴隨的認知障礙) 概要

治療藥的開發

  • CIAS開發中產品:概要
  • CIAS開發中產品:比較分析

各企業開發中的CIAS治療藥

開發中產品概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段的產品

CIAS治療藥:開發中的產品一覽 (各企業)

CIAS治療藥的開發企業

  • AbbVie Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • Avineuro Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Iproteos S.L.
  • Mnemosyne Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • Pfizer Inc.
  • Saniona AB
  • Siena Biotech S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • Sunovion Pharmaceuticals Inc. 36
  • 武田藥品工業
  • Upsher-Smith Laboratories, Inc.
  • Vanda Pharmaceuticals Inc.

CIAS:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • A-431404
    • 產品概要
    • 作用機制 (MoA)
    • 研究開發 (R&D) 的發展情形
  • AN-761
  • AQW-051
  • ASP-4345
  • ASP-5736
  • AUT-1
  • AUT-6
  • AUT-9
  • AVL-3288
  • AVN-211
  • DSP-3748
  • eltoprazine
  • encenicline hydrochloride
  • erteberel
  • IC-041
  • IPR-001
  • IPR-088
  • IPR-19
  • ITI-214
  • LUAF-64280
  • NSI-189
  • PF-04958242
  • PNU-120596
  • roflumilast
  • SEN-15924
  • SKL-15508
  • SKL-A4R
  • Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System
  • Small Molecules for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Agonize NMDA2B for CIAS
  • TAK-058
  • TAK-915

CIAS治療藥:最新的藥物簡介

CIAS治療藥:開發暫停的產品

CIAS治療藥:開發中止的產品

CIAS相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿 (全6件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8297IDB

Summary

Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
  • The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects
  • The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cognitive Impairment Associated With Schizophrenia (CIAS) Overview
    • Therapeutics Development
  • Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Amarantus Bioscience Holdings, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Coronis Partners Ltd.
    • Eli Lilly and Company
    • FORUM Pharmaceuticals Inc.
    • H. Lundbeck A/S
    • Intra-Cellular Therapies, Inc.
    • Iproteos S.L.
    • Luc Therapeutics, Inc.
    • Neuralstem, Inc.
    • Pfizer Inc.
    • Saniona AB
    • SK Biopharmaceuticals Co., Ltd.
    • Spherium Biomed S.L.
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Vanda Pharmaceuticals Inc.
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-431404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQW-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-4345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • davunetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-3748 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltoprazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erteberel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FRM-17874 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPR-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPR-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPRO-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2463359 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2814617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUAF-64280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-03463275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04958242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNU-120596 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roflumilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-15508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-A4R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-14040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-058 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-915 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0467154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant
      • Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
      • Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
      • Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis Partners Ltd., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics, Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed S.L., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2016
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top